Isu Abxis Co Ltd
KOSDAQ:086890
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Qingdao Weflo Valve Co Ltd
SZSE:002871
|
CN |
Isu Abxis Co Ltd
PP&E Net
Isu Abxis Co Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Isu Abxis Co Ltd
KOSDAQ:086890
|
PP&E Net
₩22.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Celltrion Inc
KRX:068270
|
PP&E Net
₩1.7T
|
CAGR 3-Years
19%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
PP&E Net
₩6.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
PP&E Net
₩40.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
16%
|
CAGR 10-Years
26%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
PP&E Net
₩101.1B
|
CAGR 3-Years
147%
|
CAGR 5-Years
90%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
PP&E Net
₩7.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Isu Abxis Co Ltd
Glance View
ISU Abxis Co., Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 143 full-time employees. The company went IPO on 2009-02-03. The firm operates its business under two divisions: antibody therapeutics business division and diagnostic business division. Its antibody therapeutics business division engages in the development of Cloticab, which is a monoclonal therapeutic antibody for thrombus. Its diagnostic business division engages in the provision of genetic testing services and chemotherapy response assay services for cancer examination.
See Also
What is Isu Abxis Co Ltd's PP&E Net?
PP&E Net
22.5B
KRW
Based on the financial report for Dec 31, 2025, Isu Abxis Co Ltd's PP&E Net amounts to 22.5B KRW.
What is Isu Abxis Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
7%
Over the last year, the PP&E Net growth was 3%. The average annual PP&E Net growth rates for Isu Abxis Co Ltd have been 12% over the past three years , 5% over the past five years , and 7% over the past ten years .
